KURA - Kura Oncology Should Be On Your Radar With Upcoming Presentation For Cancer Study
Kura Oncology (KURA) is a biotech that should be on everyone's radar. That's because it has an upcoming catalyst that could be a game changer. It has already reported results from its phase 2 study using Tipifarnib to treat patients with relapsed/refractory Peripheral T-cell lymphoma ((PTCL)). However, it is set to present results from the phase 2 study phase 2 study in patients with Angioimmunoblastic T-cell Lymphoma ((AITL)). Such data will be presented on December 8, 2019, at the 61st American Society of Hematology Annual meeting.
Catalyst Opportunity
A solid program from Kura